Clinical Trials Browser

Phase 2 × Lymphoma, Primary Effusion × Clear all

NCT05907759 2026-03-18

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

Phase 2 Recruiting

LymphoidSarcoma

Multi-centric Castleman's Disease, Lymphoma, Non-Hodgkin, Sarcoma, Kaposi, Lymphoma, Primary Effusion

NCT03038672 2025-11-10

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Phase 2 Active not recruiting

54 enrolled 12 charts

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT04975698 2025-10-03

BMTCTN1903

Phase 2 Active not recruiting

Lymphoma, Primary Effusion

NCT00345865 2020-07-14

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Phase 2 Completed

473 enrolled 16 charts

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Primary Effusion

NCT00183976 2014-05-22

Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

Phase 2 Terminated

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Primary Effusion